Skip to content
Inciteful Med

The Major Types of ADCA Explained

Last updated:

Autosomal Dominant Cerebellar Ataxia (ADCA) includes many genetic subtypes, such as SCA1, SCA3, and SCA6. Identifying your specific subtype through genetic testing is crucial, as it determines your unique symptoms, how fast the condition progresses, and which treatments will be most effective.

Key Takeaways

  • • ADCA encompasses several distinct genetic subtypes, commonly referred to as Spinocerebellar Ataxias (SCAs).
  • • SCA3, or Machado-Joseph Disease, is the most common type of ADCA worldwide.
  • • Progression rates vary widely by subtype, with SCA1 typically progressing fastest and SCA6 progressing the slowest.
  • • Certain subtypes require highly specialized monitoring, such as regular eye exams for vision loss in SCA7.
  • • Identifying your specific subtype can unlock targeted treatments, such as using the medication 4-aminopyridine for SCA27B.

While all forms of Autosomal Dominant Cerebellar Ataxia (ADCA) share the core symptom of incoordination, the specific “type” or subtype you have determines many details of your journey. Doctors now use genetic numbering (SCA1, SCA2, etc.) to identify these subtypes [1].

Identifying your specific subtype is vital because it allows your care team to anticipate unique symptoms—like vision loss or hearing changes—that may require specialized monitoring [2][3]. You can read more about what these subtypes mean for your future in Prognosis and Long-Term Progression.

Common Subtypes at a Glance

The table below summarizes the characteristics of the most frequently diagnosed and notable subtypes.

Subtype Progression Speed Key Hallmark Symptoms Notable Features
SCA1 Fastest [4] Severe swallowing issues (dysphagia) [5] Highest risk for early mobility aid use [5].
SCA2 Moderate [4] Slow saccades (difficulty quickly shifting the eyes) [6] High rate of lower motor neuron involvement later in life [6].
SCA3 (MJD) Moderate [4] Most common type worldwide [7] Often involves muscle twitching or parkinsonism [8].
SCA6 Slowest [4] Gaze-evoked nystagmus (eye jumping) [9] Highest 10-year survival rate (87%) [5].
SCA7 Variable Vision loss (retinal degeneration) [2] Strongest “anticipation” (earlier onset in children) [10].
SCA27B Slow/Episodic Downbeat nystagmus [11] Often responds well to 4-aminopyridine [12].
ADCA-DN Variable Deafness and Narcolepsy [3] Caused by mutations in the DNMT1 gene [13].

Deep Dive into Specific Types

SCA3 (Machado-Joseph Disease)

SCA3 is the most prevalent form of ADCA globally [7]. It is unique because it often affects systems outside the cerebellum early on. Patients may experience Cerebellar Cognitive Affective Syndrome (CCAS), which impacts mood and planning, or symptoms that look like Parkinson’s disease, such as stiffness and tremors [14][8]. Research suggests that about 75% of SCA3 patients require mobility assistance within 11 years of their first symptoms [15].

SCA7 and Vision

While most ataxias only affect eye movement, SCA7 is distinguished by its impact on the eyes themselves. It causes cone-rod dystrophy, a progressive loss of the cells in the retina that detect light and color [2]. Patients with SCA7 require regular monitoring by an ophthalmologist who specializes in retinal diseases [2].

SCA27B: A Treatable Form

SCA27B is one of the most common causes of ataxia that begins later in life [16]. It is characterized by Downbeat Nystagmus—a specific type of involuntary eye movement where the eyes drift up and “flick” downward [11]. This subtype is particularly notable because many patients see significant improvement in their balance and eye stability when treated with the medication 4-aminopyridine [12][17].

ADCA-DN

This rare subtype is caused by mutations in the DNMT1 gene [13]. It follows a very specific pattern: it typically begins with progressive hearing loss (deafness), followed by sleep attacks (narcolepsy), and eventually leads to ataxia and cognitive changes [3][18]. Management often includes a combination of hearing aids or cochlear implants and medications to manage daytime sleepiness [19].

Why Subtype Matters

Your subtype acts as a roadmap. For instance, knowing you have SCA1 might lead your doctor to monitor your swallowing more closely to prevent pneumonia [5]. If you have SCA6, you and your family can find comfort in its typically slower progression and longer life expectancy compared to other types [5]. Genetic confirmation is not just a label—it is a tool for better, more personalized care.

Frequently Asked Questions

What is the most common type of ADCA?
The most common type of ADCA worldwide is SCA3, also known as Machado-Joseph Disease. In addition to coordination problems, it frequently causes symptoms that look like Parkinson's disease, such as stiffness and muscle twitching.
Is there a treatable form of spinocerebellar ataxia?
Yes, while most forms focus on symptom management, patients with the SCA27B subtype often see significant improvements in their balance and eye stability when treated with a medication called 4-aminopyridine.
Why does it matter which SCA subtype I have?
Your specific subtype acts as a roadmap for your care. Knowing your exact type helps your doctor anticipate unique non-motor symptoms like vision or hearing loss, monitor progression accurately, and determine the most effective treatments.
Can ADCA cause vision problems?
Yes, some forms like SCA7 directly impact the eyes by causing cone-rod dystrophy, leading to progressive vision loss. Other types typically cause involuntary eye movements, such as jumping eyes or slow gaze shifting, rather than actual vision loss.
What is ADCA-DN?
ADCA-DN is a rare subtype of ataxia caused by mutations in the DNMT1 gene. It typically begins with progressive hearing loss, followed by severe daytime sleep attacks (narcolepsy), and eventually leads to coordination and cognitive changes.

Questions for Your Doctor

  • • Which specific SCA subtype do I have, and how does its typical progression rate compare to others?
  • • Should I have a specialized eye exam (retinal scan) to check for complications related to my subtype?
  • • Are there non-motor symptoms, like sleep issues or hearing loss, that I should be monitoring for based on my diagnosis?
  • • Is the medication 4-aminopyridine appropriate for my specific subtype and symptoms?
  • • How frequently should we be using tools like the SARA score to track my progression?

Questions for You

  • • Have I noticed any changes in my vision, such as colors looking duller or difficulty seeing in low light?
  • • How has my walking changed over the last year—do I feel 'steady' or am I reaching for walls more often?
  • • Have my family members mentioned any changes in my speech or my ability to follow conversations?
  • • Do I find myself acting out dreams or feeling unusually sleepy during the day?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    [Genetics of movement disorders-rare but important].

    Klebe S, Timmann D

    Der Nervenarzt 2019; (90(2)):197-210 doi:10.1007/s00115-018-0659-1.

    PMID: 30645659
  2. 2

    Functional characterization of variants of unknown significance in a spinocerebellar ataxia patient using an unsupervised machine learning pipeline.

    Nath S, Caron NS, May L, et al.

    Human genome variation 2022; (9(1)):10 doi:10.1038/s41439-022-00188-8.

    PMID: 35422034
  3. 3

    Identification of a methylation profile for DNMT1-associated autosomal dominant cerebellar ataxia, deafness, and narcolepsy.

    Kernohan KD, Cigana Schenkel L, Huang L, et al.

    Clinical epigenetics 2016; (8()):91 doi:10.1186/s13148-016-0254-x.

    PMID: 27602171
  4. 4

    Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study.

    Jacobi H, du Montcel ST, Bauer P, et al.

    The Lancet. Neurology 2015; (14(11)):1101-8.

    PMID: 26377379
  5. 5

    Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study.

    Diallo A, Jacobi H, Cook A, et al.

    The Lancet. Neurology 2018; (17(4)):327-334 doi:10.1016/S1474-4422(18)30042-5.

    PMID: 29553382
  6. 6

    Spinocerebellar ataxia type 2 followed by amyotrophic lateral sclerosis due to a pure CAG repeat expansion in ATXN2: a case report and literature review.

    Ono S, Nakamura M, Ikegami T, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2025; (46(10)):5417-5421 doi:10.1007/s10072-025-08332-2.

    PMID: 40581671
  7. 7

    Pathogenesis of SCA3 and implications for other polyglutamine diseases.

    McLoughlin HS, Moore LR, Paulson HL

    Neurobiology of disease 2020; (134()):104635 doi:10.1016/j.nbd.2019.104635.

    PMID: 31669734
  8. 8

    Autophagic vacuolar myopathy involving the phenotype of spinocerebellar ataxia type 3.

    Li J, Peng Y, Tang J, et al.

    Neuropathology : official journal of the Japanese Society of Neuropathology 2023; (43(2)):135-142 doi:10.1111/neup.12860.

    PMID: 37005010
  9. 9

    Extracerebellar Signs and Symptoms in 117 Korean Patients with Early-Stage Spinocerebellar Ataxia.

    Kim M, Ahn JH, Mun JK, et al.

    Journal of clinical neurology (Seoul, Korea) 2021; (17(2)):242-248 doi:10.3988/jcn.2021.17.2.242.

    PMID: 33835745
  10. 10

    Clinical and genetic analysis of spinocerebellar ataxia type 7 (SCA7) in Zambian families.

    Atadzhanov M, Smith DC, Mwaba MH, et al.

    Cerebellum & ataxias 2017; (4()):17 doi:10.1186/s40673-017-0075-5.

    PMID: 29214039
  11. 11

    Spinocerebellar Ataxia Type 27B can be Suspected Based on Clinical Phenotype: The Massachusetts General Hospital Ataxia Center Experience.

    Rettenmaier LA, Chen JYH, MacMore J, et al.

    Cerebellum (London, England) 2025; (24(5)):133 doi:10.1007/s12311-025-01882-3.

    PMID: 40679574
  12. 12

    Video-Oculography as a Key Diagnostic Tool for SCA27B: A Real-Life Experience.

    Coulette S, Lecler A, Le Cossec C, et al.

    European journal of neurology 2025; (32(6)):e70228 doi:10.1111/ene.70228.

    PMID: 40556471
  13. 13

    A novel DNMT1 mutation associated with early onset hereditary sensory and autonomic neuropathy, cataplexy, cerebellar atrophy, scleroderma, endocrinopathy, and common variable immune deficiency.

    Fox R, Ealing J, Murphy H, et al.

    Journal of the peripheral nervous system : JPNS 2016; (21(3)):150-3 doi:10.1111/jns.12178.

    PMID: 27277422
  14. 14

    A combination of chlorzoxazone and folic acid improves recognition memory, anxiety and depression in SCA3-84Q mice.

    Marinina KS, Bezprozvanny IB, Egorova PA

    Human molecular genetics 2024; (33(16)):1406-1419 doi:10.1093/hmg/ddae079.

    PMID: 38727562
  15. 15

    Spinocerebellar ataxia in a cohort of patients from Rio de Janeiro.

    Alvarenga MP, Siciliani LC, Carvalho RS, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2022; (43(8)):4997-5005 doi:10.1007/s10072-022-06084-x.

    PMID: 35469073
  16. 16

    Screening for SCA27B, CANVAS and other repeat expansion disorders in Greek patients with late-onset cerebellar ataxia suggests a need to update current diagnostic algorithms.

    Koutsis G, Kartanou C, Kontogeorgiou Z, et al.

    Journal of the neurological sciences 2024; (467()):123309 doi:10.1016/j.jns.2024.123309.

    PMID: 39571249
  17. 17

    Spinocerebellar ataxia 27B (SCA27B), a frequent late-onset cerebellar ataxia.

    Clément G, Puisieux S, Pellerin D, et al.

    Revue neurologique 2024; (180(5)):410-416 doi:10.1016/j.neurol.2024.03.007.

    PMID: 38609751
  18. 18

    A systematic review on the contribution of DNA methylation to hearing loss.

    Patil V, Perez-Carpena P, Lopez-Escamez JA

    Clinical epigenetics 2024; (16(1)):88 doi:10.1186/s13148-024-01697-9.

    PMID: 38970134
  19. 19

    DNMT1-associated sensory neuropathy and cerebellar ataxia: A novel variant and review of genotype-phenotype correlation.

    Menon PJ, Bogdanova-Mihaylova P, McDermott G, et al.

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):508-512 doi:10.1111/jns.12560.

    PMID: 37199681

This page provides educational information about ADCA subtypes and their typical progression. Always consult a neurologist or genetic counselor to discuss your specific diagnosis and care plan.

Stay up to date

Get notified when new research about Autosomal dominant cerebellar ataxia is published.

No spam. Unsubscribe anytime.